1a) to : (1) amplify neoantigen-specific T cells inhibited by PD-1 signalling; and (2) prime naive T cells to vaccine neoantigens. Fig. 1: Individualized mRNA neoantigen vaccines are safe, feasible and immunogenic in patients with PDAC. a,b, Trial design (a) and consolidated ...
Based on the observation that long-term survivors of PDAC mount spontaneous T cell responses against tumour-specific neoantigens not shared among patients2,3, we tested whether adjuvant individualized vaccines can stimulate neoantigen-specific T cells and provide clinical benefit in patients with su...
J. Wang., et al. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Cancer Lett. (2023) J.F. Dekkers., et al. Uncovering the mode of action of engineered T cells in patient...
在使用质谱学方法进行的研究中,鉴定了多个PDAC T细胞表位,它们可以结合多个等位基因的HLA-A,并在来自HLA相合和不相合患者的PBMC中诱导T细胞反应。目前的研究表明,其中一个表位LAMC2 203-211是基于T细胞的针对PDAC的免疫治疗的有前景的靶点。首先,发现LAMC2在包括PDAC在内的许多实体瘤中都有高表达。然而,该蛋白仅在正...
Conclusions Using MICS technology, we therefore delineate the mechanism of action of the armored CAR-T cells in PDAC xenograft model, and rule out tumor progression. Tumor-activated armored CAR T cells manifest high proliferative and metabolic activity, superior tumor penetration and killing. This is...
在胰腺导管腺癌 (PDAC) 中,自噬相关受体【autophagy-associated receptor】 NBR1 诱导肿瘤细胞表面的 MHC-I 降解,进而影响 T 细胞反应。这些发现表明,肿瘤抗原加工和呈递途径的缺陷会抑制 T 细胞启动和癌症免疫疗法的有效性。 功能失调的 DC-T 细胞相互作用 ...
研究四：Synergistic antitumor effects of mouse mesothelin-directed CAR (mmeso-CAR) T cells and αCD40 in a syngeneic model of PDAC CD40激动剂联合使用：将小鼠间皮素特异性嵌合抗原受体（mmeso-CAR） T细胞和CD40 激动剂（αCD40）联合使用，以增强CAR-T细胞和同基因小鼠模型中针对胰腺导管腺癌（PDAC）的...
他们的研究成果发表在了顶尖学术期刊《Nature》上,论文题目是 “RNA neoantigen vaccines prime long - lived CD8+T cells in pancreatic cancer” 。经过一系列深入研究,他们发现一种名为 autogene cevumeran 的 mRNA - 脂质复合物疫苗,有可能成为战胜胰腺癌的 “秘密武器”。这一发现为胰腺癌的治疗带来了新的...
使用单细胞RNA-seq和体外免疫筛选试验来识别和表征浸润胆管癌和胰腺癌的新抗原反应性T细胞,结果发现大多数CD8+和CD4+新抗原反应性T细胞具有明显转录组特征的耗竭特征。2022年4月11日,在Cancer cell杂志上发表了一篇“Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers”的文章,...
[1]Leidner R,et al.Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 2022 Jun 2;386(22):2112-2119. doi: 10.1056/NEJMoa2119662..https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531755/ [2]Greenbaum U,et al.Engineered T-cell Receptor T Cells for Cancer ...